T-cell lymphoma: Microenvironment-related biomarkers

Seminars in Cancer Biology

Volumn 34, Issue , 2015, Pages 46-51

  Tse, Eric ^a   Kwong, Yok Lam ^a  

^a QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

Biomarkers; Cytokines; Gene expression profiling; Microenvironment; T cell lymphomas

Indexed keywords

CXCL13 CHEMOKINE; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 21; INTERLEUKIN 6; INTERLEUKIN 8; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN BCL 6; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; RUXOLITINIB; STAT3 PROTEIN; STAT6 PROTEIN; TUMOR MARKER; VASCULOTROPIN; BIOLOGICAL MARKER; VASCULOTROPIN A;

ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; ANTINEOPLASTIC ACTIVITY; BCL6 GENE; BLOOD VESSEL; CANCER PROGNOSIS; CARCINOGENESIS; CELL FUNCTION; CELL INTERACTION; CXCL13 GENE; ENDOTHELIUM CELL; EOSINOPHIL; FOLLICULAR LYMPHOMA; GENE; GENE EXPRESSION PROFILING; LARGE CELL LYMPHOMA; LYMPHOCYTE; MACROPHAGE; PD 1 GENE; REVIEW; RHOA GENE; SOMATIC MUTATION; STAT3 GENE; T CELL LYMPHOMA; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; ANIMAL; CELL COMMUNICATION; HUMAN; IMMUNOLOGY; LYMPHOCYTE SUBPOPULATION; LYMPHOMA, T-CELL; METABOLISM; MORTALITY; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PROGNOSIS;

ANIMALS; BIOMARKERS; CELL COMMUNICATION; ENDOTHELIAL CELLS; EOSINOPHILS; HUMANS; LYMPHOCYTE SUBSETS; LYMPHOMA, T-CELL; MACROPHAGES; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; TUMOR MICROENVIRONMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84942297665     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2015.06.001     Document Type: Review

References (57)

1. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008, IARC. 4th ed.
2. Vose J., Armitage J., Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J. Clin. Oncol. 2008, 26:4124-4130.
3. Tsukasaki K., Tobinai K. Biology and treatment of HTLV-1 associated T-cell lymphomas. Best Pract. Res. Clin. Haematol. 2013, 26:3-14.
4. Tse E., Kwong Y.L. How I treat NK/T-cell lymphomas. Blood 2013, 121:4997-5005.
5. Gaulard P., de Leval L. The microenvironment in T-cell lymphomas: emerging themes. Semin. Cancer Biol. 2014, 24:49-60.
6. Lenz G., Wright G., Dave S.S., Xiao W., Powell J., Zhao H., et al. Stromal gene signatures in large-B-cell lymphomas. N. Engl. J. Med. 2008, 359:2313-2323.
7. Dave S.S., Wright G., Tan B., Rosenwald A., Gascoyne R.D., Chan W.C., et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N. Engl. J. Med. 2004, 351:2159-2169.
8. Yoo H.Y., Sung M.K., Lee S.H., Kim S., Lee H., Park S., et al. A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma. Nat. Genet. 2014, 46:371-375.
9. Sakata-Yanagimoto M., Enami T., Yoshida K., Shiraishi Y., Ishii R., Miyake Y., et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat. Genet. 2014, 46:171-175.
10. Palomero T., Couronne L., Khiabanian H., Kim M.Y., Ambesi-Impiombato A., Perez-Garcia A., et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat. Genet. 2014, 46:166-170.
11. Koskela H.L., Eldfors S., Ellonen P., van Adrichem A.J., Kuusanmaki H., Andersson E.I., et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N. Engl. J. Med. 2012, 366:1905-1913.
12. Piccaluga P.P., Fuligni F., De Leo A., Bertuzzi C., Rossi M., Bacci F., et al. Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy study. J. Clin. Oncol. 2013, 31:3019-3025.
13. Iqbal J., Weisenburger D.D., Greiner T.C., Vose J.M., McKeithan T., Kucuk C., et al. Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood 2010, 115:1026-1036.
14. Iqbal J., Wright G., Wang C., Rosenwald A., Gascoyne R.D., Weisenburger D.D., et al. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood 2014, 123:2915-2923.
15. Wang T., Feldman A.L., Wada D.A., Lu Y., Polk A., Briski R., et al. GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features. Blood 2014, 123:3007-3015.
16. FH) cells. Blood 2007, 109:4952-4963.
17. Ramiscal R.R., Vinuesa C.G. T-cell subsets in the germinal center. Immunol. Rev. 2013, 252:146-155.
18. Ahearne M.J., Allchin R.L., Fox C.P., Wagner S.D. Follicular helper T-cells: expanding roles in T-cell lymphoma and targets for treatment. Br. J. Haematol. 2014, 166:326-335.
19. Zhao W.L., Mourah S., Mounier N., Leboeuf C., Daneshpouy M.E., Legres L., et al. Vascular endothelial growth factor-A is expressed both on lymphoma cells and endothelial cells in angioimmunoblastic T-cell lymphoma and related to lymphoma progression. Lab. Invest. 2004, 84:1512-1519.
20. h17 cells contribute to the lymphoma-associated pro-inflammatory microenvironment of angioimmunoblastic T-cell lymphoma. Am. J. Pathol. 2010, 177:792-802.
21. Condeelis J., Pollard J.W. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006, 124:263-266.
22. Mantovani A., Biswas S.K., Galdiero M.R., Sica A., Locati M. Macrophage plasticity and polarization in tissue repair and remodelling. J. Pathol. 2013, 229:176-185.
23. Sica A., Larghi P., Mancino A., Rubino L., Porta C., Totaro M.G., et al. Macrophage polarization in tumour progression. Semin. Cancer Biol. 2008, 18:349-355.
24. Suresh T., Lee L.X., Joshi J., Barta S.K. New antibody approaches to lymphoma therapy. J. Hematol. Oncol. 2014, 7:58.
25. Niino D., Komohara Y., Murayama T., Aoki R., Kimura Y., Hashikawa K., et al. Ratio of M2 macrophage expression is closely associated with poor prognosis for Angioimmunoblastic T-cell lymphoma (AITL). Pathol. Int. 2010, 60:278-283.
26. Sugaya M., Miyagaki T., Ohmatsu H., Suga H., Kai H., Kamata M., et al. Association of the numbers of CD163(+) cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma. J. Dermatol. Sci. 2012, 68:45-51.
27. Komohara Y., Niino D., Saito Y., Ohnishi K., Horlad H., Ohshima K., et al. Clinical significance of CD163(+) tumor-associated macrophages in patients with adult T-cell leukemia/lymphoma. Cancer Sci. 2013, 104:945-951.
28. Chanmee T., Ontong P., Konno K., Itano N. Tumor-associated macrophages as major players in the tumor microenvironment. Cancers (Basel) 2014, 6:1670-1690.
29. Lin Z.X., Bai B., Cai Q.C., Cai Q.Q., Wang X.X., Wu X.Y., et al. High numbers of tumor-associated macrophages correlate with poor prognosis in patients with mature T- and natural killer cell lymphomas. Med. Oncol. 2012, 29:3522-3528.
30. Zhang W., Wang L., Zhou D., Cui Q., Zhao D., Wu Y. Expression of tumor-associated macrophages and vascular endothelial growth factor correlates with poor prognosis of peripheral T-cell lymphoma, not otherwise specified. Leuk. Lymphoma 2011, 52:46-52.
31. Wu X., Schulte B.C., Zhou Y., Haribhai D., Mackinnon A.C., Plaza J.A., et al. Depletion of M2-like tumor-associated macrophages delays cutaneous T-cell lymphoma development in vivo. J. Invest. Dermatol. 2014, 134:2814-2822.
32. Brauninger A., Spieker T., Willenbrock K., Gaulard P., Wacker H.H., Rajewsky K., et al. Survival and clonal expansion of mutating "forbidden" (immunoglobulin receptor-deficient) Epstein-Barr virus-infected B cells in angioimmunoblastic T cell lymphoma. J. Exp. Med. 2001, 194:927-940.
33. Choi Y.S., Kageyama R., Eto D., Escobar T.C., Johnston R.J., Monticelli L., et al. ICOS receptor instructs T follicular helper cell versus effector cell differentiation via induction of the transcriptional repressor Bcl6. Immunity 2011, 34:932-946.
34. Delfau-Larue M.H., de Leval L., Joly B., Plonquet A., Challine D., Parrens M., et al. Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA. Haematologica 2012, 97:1594-1602.
35. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000, 101:455-458.
36. Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-1061.
37. Bruneau J., Canioni D., Renand A., Marafioti T., Paterson J.C., Martin-Garcia N., et al. Regulatory T-cell depletion in angioimmunoblastic T-cell lymphoma. Am. J. Pathol. 2010, 177:570-574.
38. Whiteside T.L. Regulatory T cell subsets in human cancer: are they regulating for or against tumor progression?. Cancer Immunol. Immunother. 2014, 63:67-72.
39. Wang J., Ke X.Y. The four types of Tregs in malignant lymphomas. J. Hematol. Oncol. 2011, 4:50.
40. Whiteside T.L. What are regulatory T cells (Treg) regulating in cancer and why?. Semin. Cancer Biol. 2012, 22:327-334.
41. Kim W.Y., Jeon Y.K., Kim T.M., Kim J.E., Kim Y.A., Lee S.H., et al. Increased quantity of tumor-infiltrating FOXP3-positive regulatory T cells is an independent predictor for improved clinical outcome in extranodal NK/T-cell lymphoma. Ann. Oncol. 2009, 20:1688-1696.
42. Gjerdrum L.M., Woetmann A., Odum N., Burton C.M., Rossen K., Skovgaard G.L., et al. FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival. Leukemia 2007, 21:2512-2518.
43. Au W.Y., Pang A., Choy C., Chim C.S., Kwong Y.L. Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood 2004, 104:243-249.
44. Ganjoo K., Hong F., Horning S.J., Gascoyne R.D., Natkunam Y., Swinnen L.J., et al. Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404). Leuk. Lymphoma 2014, 55:768-772.
45. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 2012, 12:252-264.
46. Ansell S.M., Lesokhin A.M., Borrello I., Halwani A., Scott E.C., Gutierrez M., et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N. Engl. J. Med. 2015, 372:311-319.
47. Munir S., Andersen G.H., Woetmann A., Odum N., Becker J.C., Andersen M.H. Cutaneous T cell lymphoma cells are targets for immune checkpoint ligand PD-L1-specific, cytotoxic T cells. Leukemia 2013, 27:2251-2253.
48. Chen B.J., Chapuy B., Ouyang J., Sun H.H., Roemer M.G., Xu M.L., et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin. Cancer Res. 2013, 19:3462-3473.
49. Roufosse F., Garaud S., de Leval L. Lymphoproliferative disorders associated with hypereosinophilia. Semin. Hematol. 2012, 49:138-148.
50. Ohshima K.S., Suzumiya J., Kawasaki C., Kanda M., Kikuchi M. Cytoplasmic cytokines in lymphoproliferative disorders: multiple cytokine production in angioimmunoblastic lymphadenopathy with dysproteinemia. Leuk. Lymphoma 2000, 38:541-545.
51. h2 environment of cutaneous T-cell lymphoma. J. Invest. Dermatol. 2010, 130:2304-2311.
52. Lacy P., Moqbel R. Eosinophil cytokines. Chem. Immunol. 2000, 76:134-155.
53. Sausville E.A., Eddy J.L., Makuch R.W., Fischmann A.B., Schechter G.P., Matthews M., et al. Histopathologic staging at initial diagnosis of mycosis fungoides and the Sezary syndrome. Definition of three distinctive prognostic groups. Ann. Intern. Med. 1988, 109:372-382.
54. Mourad N., Mounier N., Briere J., Raffoux E., Delmer A., Feller A., et al. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood 2008, 111:4463-4470.
55. Zhao S., Zhang L., Zhang M., Yao G., Zhang X., Zhao W., et al. Angioimmunoblastic T-cell lymphoma: the effect of initial treatment and microvascular density in 31 patients. Med. Oncol. 2012, 29:2311-2316.
56. Aguiar Bujanda D. Complete response of relapsed angioimmunoblastic T-cell lymphoma following therapy with bevacizumab. Ann. Oncol. 2008, 19:396-397.
57. Bruns I., Fox F., Reinecke P., Kobbe G., Kronenwett R., Jung G., et al. Complete remission in a patient with relapsed angioimmunoblastic T-cell lymphoma following treatment with bevacizumab. Leukemia 2005, 19:1993-1995.